Search

Your search keyword '"Sahmoud, T."' showing total 314 results
Start Over Author "Sahmoud, T."
314 results on '"Sahmoud, T."'

7. Abstract P1-10-08: Development of a first-in-class oral selective ERα covalent antagonist (SERCA) for the treatment of ERαWT and ERαMUT breast cancer

Author

Korpal, M, primary, Puyang, X, additional, Furman, C, additional, Zheng, GZ, additional, Banka, D, additional, Wu, J, additional, Zhang, Z, additional, Thomas, M, additional, Mackenzie, C, additional, Yao, H, additional, Rimkunas, V, additional, Kumar, P, additional, Caleb, B, additional, Karr, C, additional, Subramanian, V, additional, Irwin, S, additional, Larsen, N, additional, Vaillancourt, F, additional, Nguyen, T-V, additional, Davis, A, additional, Chan, B, additional, Hao, MH, additional, O'Shea, M, additional, Prajapati, S, additional, Agoulnik, S, additional, Kuznetsov, G, additional, Kumar, N, additional, Yu, Y, additional, Lai, G, additional, Hart, A, additional, Eckley, S, additional, Fekkes, P, additional, Bowser, T, additional, Joshi, JJ, additional, Selvaraj, A, additional, Wardell, S, additional, Norris, J, additional, Smith, S, additional, Reynolds, D, additional, Mitchell, L, additional, Wang, J, additional, Yu, L, additional, Kim, A, additional, Rioux, N, additional, Sahmoud, T, additional, Warmuth, M, additional, Smith, PG, additional, and Zhu, P, additional

Published
2018
Full Text
View/download PDF

8. Characterization of Novel Oral Splicing Modulator, H3B-8800, Identifies the Mechanistic Basis for its Preferential Lethality Towards Spliceosome-Mutant Myeloid Malignancy Models

Author

Buonamici, S., primary, Yoshimi, A., additional, Thomas, M., additional, Seiler, M., additional, Chan, B., additional, Csibi, A., additional, Fekkes, P., additional, Klimek, V., additional, Kumar, P., additional, Lee, S.C.W., additional, Padron, E., additional, Pazolli, E., additional, Goldberg, J., additional, Sahmoud, T., additional, Taylor, J., additional, Warmuth, M., additional, Yu, L., additional, Zhu, P., additional, Abdel-Wahab, O., additional, and Smith, P., additional

Published
2017
Full Text
View/download PDF

9. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

Author

Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC Trialists' Group, DE LAURENTIIS, MICHELINO, DE PLACIDO, SABINO, CARLOMAGNO, Chiara, Baum, M, Buzdar, A, Cuzick, J, Forbes, J, Houghton, J, Howell, A, Sahmoud, T, ATAC Trialists', Group, DE LAURENTIIS, Michelino, DE PLACIDO, Sabino, and Carlomagno, Chiara

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Antineoplastic Agents, Hormonal, medicine.drug_class, Population, Anastrozole, Breast Neoplasms, Disease-Free Survival, Breast cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Nitriles, medicine, Humans, Enzyme Inhibitors, education, Gynecology, education.field_of_study, Aromatase inhibitor, Aromatase Inhibitors, business.industry, Endometrial cancer, Hazard ratio, Triazoles, medicine.disease, Survival Analysis, Postmenopause, Tamoxifen, Treatment Outcome, Tolerability, Chemotherapy, Adjuvant, Female, Neoplasm Recurrence, Local, business, Follow-Up Studies, medicine.drug
Abstract

BACKGROUND: The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow-up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer, anastrozole was superior to tamoxifen in terms of disease-free survival (DFS), time to recurrence (TTR), and incidence of contralateral breast cancer (CLBC). In the current article, the results of the first efficacy update, based on a median follow-up period of 47 months, are reported along with the results of an updated safety analysis, performed 7 months after the first analysis (median duration of treatment, 36.9 months). METHODS: DFS, TTR, CLBC incidence, and safety were assessed in the same patient group as in the first analysis of the ATAC trial. RESULTS: DFS estimates at 4 years remained significantly more favorable (86.9% vs. 84.5%, respectively) for patients receiving anastrozole compared with those receiving tamoxifen (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.76-0.99; P = 0.03). The benefit generated by anastrozole in terms of DFS was even greater in patients with hormone receptor-positive tumors (HR, 0.82; 95% CI, 0.70-0.96; P = 0.014). The HR for TTR also indicated a significant benefit for patients receiving anastrozole compared with those receiving tamoxifen (HR, 0.83; 95% CI, 0.71-0.96; P = 0.015), with additional benefit for patients with hormone receptor-positive tumors (HR, 0.78; 95% CI, 0.65-0.93; P = 0.007). CLBC incidence data also continued to favor anastrozole (odds ratio [OR], 0.62; 95% CI, 0.38-1.02; P = 0.062), and statistical significance was achieved in the hormone receptor-positive subgroup (OR, 0.56; 95% CI, 0.32-0.98; P = 0.042). The updated safety analysis also confirmed the findings of the first analysis, in that endometrial cancer (P = 0.007), vaginal bleeding and discharge (P < 0.001 for both), cerebrovascular events (P < 0.001), venous thromboembolic events (P < 0.001), and hot flashes (P < 0.001) all occurred less frequently in the anastrozole group, whereas musculoskeletal disorders and fractures (P < 0.001 for both) continued to occur less frequently in the tamoxifen group. These results indicated that the safety profile of anastrozole remained consistent. CONCLUSIONS: After an additional follow-up period, anastrozole continues to show superior efficacy, which is most apparent in the clinically relevant hormone receptor-positive population. Furthermore, anastrozole has numerous noteworthy advantages in terms of tolerability compared with tamoxifen. These findings suggest that the benefits of anastrozole are likely to be maintained in the long term and provide further support for the status of anastrozole as a valid treatment option for postmenopausal women with hormone-sensitive early-stage breast cancer. Copyright 2003 American Cancer Society.

Published
2003

10. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

Author

Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, ATAC Trialists' Group, DE LAURENTIIS, MICHELINO, DE PLACIDO, SABINO, CARLOMAGNO, Chiara, Baum, M, Budzar, Au, Cuzick, J, Forbes, J, Houghton, Jh, Klijn, Jg, Sahmoud, T, ATAC Trialists', Group, DE LAURENTIIS, Michelino, DE PLACIDO, Sabino, and Carlomagno, Chiara

Published
2002

11. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer

Author

Lise, M, Nitti, Donato, Marchet, A, Sahmoud, T, Buyse, M, Duez, N, Fiorentino, M, GUIMARAES DOS SANTOS, J, Labianca, R, Rougier, P, Gignooux, M, and Pedrazzoli, S.

Subjects
Male, Oncology, Cancer Research, medicine.medical_specialty, Mitomycin, medicine.medical_treatment, Adenocarcinoma, Disease-Free Survival, law.invention, Randomized controlled trial, Stomach Neoplasms, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Doxorubicin, Proportional Hazards Models, Chemotherapy, business.industry, Cancer, medicine.disease, Combined Modality Therapy, Surgery, Europe, Survival Rate, Clinical trial, Regimen, Chemotherapy, Adjuvant, Fluorouracil, Female, business, medicine.drug
Abstract

PURPOSE In a randomized clinical trial (European Organization for the Research and Treatment of Cancer [EORTC] no. 40813) on adjuvant chemotherapy in gastric cancer, results obtained after administration of the FAM2 regimen (fluorouracil [5-FU], doxorubicin, and mitomycin) were compared with results obtained after surgery alone to assess the effect of this regimen on overall survival, time to progression, and disease-free interval. PATIENTS AND METHODS Three hundred fourteen patients who had undergone curative resection for stage II or stage III (International Union Against Cancer [UICC] 1978) gastric adenocarcinoma were randomized to receive chemotherapy (treatment arm) or no further treatment (control arm). The chemotherapy schedule was repeated every 43 days for seven cycles. The log-rank test and the Cox model were used for statistical analysis. RESULTS Of 314 patients, 159 comprised the control group and 155 the FAM2 group. Nineteen FAM2 patients never received chemotherapy. The median number of cycles was five. Of the patients started on adjuvant treatment, severe hematologic and nonhematologic toxicity (grades 3 or 4, World Health Organization [WHO] scale) occurred, respectively, in 6% to 9% and in 1% to 29% of cases. The overall 5-year survival rate was 70% for stage II and 32% for stage III patients. No statistically significant difference was found between overall survival of the two treatment arms (P = .295). However, time to progression was significantly delayed in the FAM2 arm (P = .020) and disease-free survival showed borderline significance (P = .068). CONCLUSION FAM2, in view of its high toxicity, cannot be advocated as standard adjuvant treatment for gastric cancer. Large-scale clinical trials using more active, less toxic regimens are required to demonstrate whether adjuvant chemotherapy provides any real benefit.

Published
1995
Full Text
View/download PDF

12. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group Study

Author

Schornagel, J.H., Verweij, J., Mulder, P.H.M. de, Cognetti, F., Vermorken, J.B., Cappelaere, P., Armand, J.P., Wildiers, J., Graeff, A. de, Clavel, M., Sahmoud, T., Kirkpatrick, A., and Lefebvre, J.L.

Subjects
Blood Cells, Leukemia, Lymphoma, Mycoses, Bacterial Infections, Infection, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), Combined Modality Therapy, Magnetic Resonance Imaging
Abstract

Contains fulltext : 20987___.PDF (Publisher’s version ) (Open Access)

Published
1995

13. Everolimus treatment of subependymal giant cell astrocytomas (SEGA's) associated with tuberous sclerosis complex (TSC): the EXIST-I trial

Author

Sparagana, S., Belousova, Elena, Jozwiak, Sergiusz, Korf, Bruce, Frost, M., Kuperman, Rachel, Kohrman, M., Witt, Olaf, Wu, J., Flamini, Robert, Jansen, Anna, Curtalolo, P., Thiele, Elizabeth, Whittemore, V., De Vries, Petrus, Ford, James, Shah, Gaurav, Cauwel, H., Edrich, Pascal, Sahmoud, T., Franz, David, Neuro-oncology, Society For, Public Health Care, and Neurogenetics

Subjects
Tuberous sclerosis complex (TSC), Everolimus therapy, TRIAL
Abstract

TSC is a genetic disorder caused by mutations in either the TSC1 (encoding hamartin) or TSC2 (encoding tuberin) genes. Hamartin and tuberin normally form a dimer that inhibits mammalian target of rapamycin (mTOR); mutation of either TSC1 or TSC2 results in constitutive mTOR activation. CNS manifestations of TSC include cortical tubers, SEGA, epilepsy, mental retardation, and autism. Everolimus, an mTOR inhibitor, has recently demonstrated efficacy in an open-label phase 1/2 study, significantly reducing SEGA volume and frequency of epileptic seizures (Krueger et al. NEJM 2010; 363:1801-11). Based on these results, everolimus was approved by the FDA in 2010 for patients with SEGA not suitable for surgical resection. A double-blind, randomized, placebo-controlled, multicenter phase 3 study (EXIST-1; NCT00789828) is underway to further evaluate everolimus in patients with SEGA associated with TSC. Eligible patients (target ¼ 99), stratified by use of anti-epileptic drugs and randomized 2:1 to receive everolimus or placebo, received oral everolimus starting at 4.5 mg/m2/d (titrated to a blood trough level of 5-15 ng/mL). Brain MRI was performed at 3, 6, and 12 months after initiation of study treatment and annually thereafter until SEGA progression. Patients completed a 24-hour video electroencephalogram at baseline and at 6 months (or end of treatment for discontinuing patients). Skin lesions were assessed using the Physician's Global Assessment of Clinical Condition tool every 3 months. Blood was collected for analysis of PK, hematology, blood chemistry, plasma angiogenic molecules, and gene mutation analysis for TSC1 and TSC2 at baseline. Patients experiencing SEGA progression were unblinded, placebo patients were offered open-label everolimus, and they were then followed using the most recent brain MRI scan as baseline and taking further brain MRI scans at 3, 6, and 12 months and annually thereafter. Open-label treatment continued until SEGA progression. Efficacy and safety outcomes are expected in mid-2011 and will be presented.

Published
2011

16. PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer

Author

Sotiropoulou, G, Loi, S, Michiels, S, Baselga, J, Bartlett, JMS, Singhal, SK, Sabine, VS, Sims, AH, Sahmoud, T, Dixon, JM, Piccart, MJ, Sotiriou, C, Sotiropoulou, G, Loi, S, Michiels, S, Baselga, J, Bartlett, JMS, Singhal, SK, Sabine, VS, Sims, AH, Sahmoud, T, Dixon, JM, Piccart, MJ, and Sotiriou, C

Abstract

The phosphatidylinositol 3' kinase (PI3K) pathway is commonly activated in breast cancer and aberrations such as PI3K mutations are common. Recent exciting clinical trial results in advanced estrogen receptor-positive (ER) breast cancer support mTOR activation is a major means of estrogen-independent tumor growth. Hence the means to identify a responsive breast cancer population that would most benefit from these compounds in the adjuvant or earlier stage setting is of high interest. Here we study PIK3CA genotype as well as a previously reported PI3K/mTOR-pathway gene signature (PIK3CA-GS) and their ability to estimate the level of PI3K pathway activation in two clinical trials of newly diagnosed ER-positive breast cancer patients- a total of 81 patients- one of which was randomized between letrozole and placebo vs letrozole and everolimus. The main objectives were to correlate the baseline PIK3CA genotype and GS with the relative change from baseline to day 15 in Ki67 (which has been shown to be prognostic in breast cancer) and phosphorylated S6 (S240) immunohistochemistry (a substrate of mTOR). In the randomized dataset, the PIK3CA-GS could identify those patients with the largest relative decreases in Ki67 to letrozole/everolimus (R = -0.43, p = 0.008) compared with letrozole/placebo (R = 0.07, p = 0.58; interaction test p = 0.02). In a second dataset of pre-surgical everolimus alone, the PIK3CA-GS was not significantly correlated with relative change in Ki67 (R = -0.11, p = 0.37) but with relative change in phosphorlyated S6 (S240) (R = -0.46, p = 0.028). PIK3CA genotype was not significantly associated with any endpoint in either datasets. Our results suggest that the PIK3CA-GS has potential to identify those ER-positive BCs who may benefit from the addition of everolimus to letrozole. Further evaluation of the PIK3CA-GS as a predictive biomarker is warranted as it may facilitate better selection of responsive patient populations for mTOR inhibition in combinat

Published
2013

18. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer

Author

Giaccone, G., Splinter, T. A., Debruyne, C., Kho, G. S., Lianes, P., Nico van Zandwijk, Pennucci, M. C., Scagliotti, G., Meerbeeck, J., Hoesel, Q., Curran, D., Sahmoud, T., Postmus, P. E., Medical Oncology, and Pulmonary Medicine

Subjects
Adult, Male, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Lung Neoplasms, Middle Aged, Paclitaxel, Quality of Life, Random Allocation, Survival Rate, Teniposide, Treatment Outcome, Oncology, Cancer Research, Carcinoma, Experimental diagnostics and therapy of malignancies, SDG 3 - Good Health and Well-being, Non-Small-Cell Lung
Abstract

Item does not contain fulltext

Published
1998

20. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC lung cancer cooperative group

Author

Nico van Zandwijk, Groen, Hjm, Postmus, Pe, Burghouts, Jtw, Tenvelde, Gpm, Ardizzoni, A., Smith, Ie, Baas, P., Sahmoud, T., Kirkpatrick, A., Dalesio, O., Giaccone, G., Faculteit Medische Wetenschappen/UMCG, Damage and Repair in Cancer Development and Cancer Treatment (DARE), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
ALPHA, CARCINOMA, maintenance therapy, ONCOLOGY-GROUP, small cell lung cancer, CHEMOTHERAPY, interferon type II, rIFN-gamma, THERAPY, CLINICAL-TRIAL
Abstract

This study was undertaken to determine if recombinant interferon-gamma (rIFN-gamma) given every other day as maintenance therapy could prolong the survival of patients with small cell lung cancer (SCLC) who achieved a complete or nearly-complete response to induction therapy. A secondary endpoint was to assess the toxicity of alternate day doses of this treatment. One hundred and seventy seven patients in complete or nearly-complete response following chemotherapy with or without thoracic radiotherapy were studied. Patients were randomised to receive either rIFN-gamma 4 million units (0.2 mg) subcutaneously every other day for 4 months or observation. One hundred and twenty of the 127 registered patients were eligible; 59 patients received IFN and 61 patients without maintenance therapy were followed. Alternate day IFN was reasonably well tolerated by the majority of patients, but in 12% substantial non-haematological toxicity (including flu-like syndrome) occurred. One of 3 patients with pneumonitis died after having received 3.6 mg IFN. The median survival time from the date of randomisation was 8.9 months for the IFN arm and 9.9 months for the observation arm. rIFN-gamma at the dose and schedule used in this study failed to prolong response duration and survival in SCLC patients in complete or nearly-complete response. The toxicity seen with every other day doses of IFN was less than that reported with daily dosing. The hypothesis that this agent may increase the deleterious effects of radiation on normal lung tissue was supported by the development of pneumonitis in 3 cases of whom 1 had a fatal outcome. The results do not warrant further studies with rIFN-gamma on maintaining response in SCLC. (C) 1997 Elsevier Science Ltd.

Published
1997

21. Reply

Author

Sahmoud, T, Sylvester, R, Modigliani, R, and Mary, J-Y

Subjects
Letters to the Editor
Published
1996

24. Bolero-2: A Randomized Phase III Study of Everolimus in Combination with Exemestane: Results of the Japanese Subgroup Analysis

Author

Ito, Y., primary, Masuda, N., additional, Iwata, H., additional, Mukai, H., additional, Horiguchi, J., additional, Tokuda, Y., additional, Kuroi, K., additional, Iwase, H., additional, Inaji, H., additional, Ohsumi, S., additional, Nakayama, T., additional, Ohno, S., additional, Sahmoud, T., additional, Ohno, N., additional, and Noguchi, S., additional

Published
2012
Full Text
View/download PDF

25. Granite-1; Phase III Trial of Everolimus (EVE) in Previously Treated Patients with Advanced Gastric Cancer (AGC): Results of Japanese Population

Author

Chin, K., primary, Muro, K., additional, Doi, T., additional, Warita, E., additional, Kudo, T., additional, Nishina, T., additional, Furuse, J., additional, Komatsu, Y., additional, Yamaguchi, K., additional, Kato, S., additional, Takiuchi, H., additional, Koizumi, W., additional, Sahmoud, T., additional, Ohno, N., additional, and Ohtsu, A., additional

Published
2012
Full Text
View/download PDF

31. Everolimus for the Treatment of Renal Angiomyolipoma in Patients with Tuberous Sclerosis Complex Being Treated for Subependymal Giant Cell Astrocytoma (S45.001)

Author

Franz, D., primary, Belousova, E., additional, Frost, M., additional, Kuperman, R., additional, Bebin, M., additional, Korf, B., additional, Flamini, R., additional, Kohrman, M., additional, Sparagana, S., additional, Wu, J., additional, Sahmoud, T., additional, Shah, G., additional, and Jozwiak, S., additional

Published
2012
Full Text
View/download PDF

32. Everolimus for the Treatment of Angiomyolipoma in Patients with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis: Results from EXIST-2 (P04.188)

Author

Frost, M., primary, Budde, K., additional, Kingswood, J., additional, Zonnenberg, B., additional, Belousova, E., additional, Radzikowska, E., additional, Sauter, M., additional, Nonomura, N., additional, Brakemeier, S., additional, de Vries, P., additional, Sahmoud, T., additional, Shah, G., additional, Miao, S., additional, Gray, D., additional, and Bissler, J., additional

Published
2012
Full Text
View/download PDF

36. 80 Everolimus in the treatment of angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: Results from EXIST-2

Author

Budde, K., primary, Kingswood, C., additional, Zonnenberg, B., additional, Frost, M., additional, Belousova, E., additional, Sauter, M., additional, Fischereder, M., additional, Nonomura, A., additional, Bebin, M., additional, Pei, Y., additional, Brakemeier, S., additional, Sahmoud, T., additional, Shah, G., additional, Lincy, J., additional, and Bissler, J., additional

Published
2012
Full Text
View/download PDF

37. 74 The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma

Author

Jozwiak, S., primary, Belousova, E., additional, Kingswood, C., additional, Frost, M., additional, Kuperman, R., additional, Bebin, M., additional, Korf, B., additional, Flamini, R., additional, Kohrman, M., additional, Sparagana, S., additional, Wu, J., additional, Sahmoud, T., additional, Shah, G., additional, and Franz, D., additional

Published
2012
Full Text
View/download PDF

38. TENIPOSIDE FOR BRAIN METASTASES OF SMALL-CELL LUNG-CANCER - A PHASE-II STUDY

Author

Postmus, Pe, Smit, Ef, Haaxmareiche, H., Nico van Zandwijk, Ardizzoni, A., Quoix, E., Kirkpatrick, A., Sahmoud, T., Giaccone, G., and Faculteit Medische Wetenschappen/UMCG

Subjects
BRONCHOGENIC CARCINOMA, COMBINATION CHEMOTHERAPY, SURVIVAL, FREQUENCY, CNS METASTASES, VM26, IRRADIATION
Abstract

Purpose: Here we report the results of a phase II study of teniposide, one of the most active drugs against small-cell lung cancer (SCLC), in patients with brain metastases. Patients and Methods: Patients with SCLC who presented with brain metastases at diagnosis (n = 11) or during follow-up evaluation after treatment (n = 69) were treated with teniposide at a dose of 150 mg/m(2) intravenously on days 1, 3, and 5 at 3-week intervals in an outpatient setting. Response in the brain was evaluated by brain computed tomography (CT) after two, six, and 12 courses. Results: In 26 of 80 assessable patients, an intracranial response was seen, with a response rate of 33% (95% confidence interval, 22% to 44%). The median response duration was 5.4 months for patients with a complete response (CR) and 4.2 months for patients with a partial response (PR). Patients who required corticosteroids for peritumoral edema had a significantly lower response rate than patients who did not receive corticosteroids. Neurologic function at the start of treatment had a significant influence (neurologic function 1 better than 2, respectively, better than 3 and 4; P 5 cycles; P = .043). Grade 3/4 leukocytopenia and thrombocytopenia were seen in 3% and 39%, respectively, of 80 patients. Toxicity-related death was seen in eight patients, seven of whom were previously treated with chemotherapy Conclusion: Teniposide is active against brain metastases of SCLC. It is a suitable drug for palliation, especially of patients without extensive pretreatment and with a good neurologic function and performance status. Patients previously treated with cranial radiotherapy are also candidates for this therapy. If systemic chemotherapy is considered for tumor progression outside the brain, radiotherapy of brain metastases might be omitted or delayed pending the effect of chemotherapy. The use of corticosteroids in patients with brain metastases treated with chemotherapy might influence the efficacy of the chemotherapy. (C) 1995 by American Society of Clinical Oncology.

Published
1995

41. MEDICAL AND NEURO-ONCOLOGY

Author

Prithviraj, G. K., primary, Sommers, S. R., additional, Jump, R. L., additional, Halmos, B., additional, Chambless, L. B., additional, Parker, S. L., additional, Hassam-Malani, L., additional, McGirt, M. J., additional, Thompson, R. C., additional, Hunter, K., additional, Chamberlain, M. C., additional, Le, E. M., additional, Lee, E. L. T., additional, Sadighi, Z. S., additional, Pearlman, M. L., additional, Slopis, J. M., additional, Vats, T. S., additional, Khatua, S., additional, DeVito, N. C., additional, Yu, M., additional, Chen, R., additional, Pan, E., additional, Cloughesy, T., additional, Raizer, J., additional, Drappatz, J., additional, Gerena-Lewis, M., additional, Rogerio, J., additional, Yacoub, S., additional, Desjardin, A., additional, Groves, M. D., additional, DeGroot, J., additional, Loghin, M., additional, Conrad, C. A., additional, Hess, K., additional, Ni, J., additional, Ictech, S., additional, Yung, W. A., additional, Porter, A. B., additional, Dueck, A. C., additional, Karlin, N. J., additional, Olson, J., additional, Silber, J., additional, Reiner, A. S., additional, Panageas, K. S., additional, Iwamoto, F. M., additional, Cloughesy, T. F., additional, Aldape, K. D., additional, Rivera, A. L., additional, Eichler, A. F., additional, Louis, D. N., additional, Paleologos, N. A., additional, Fisher, B. J., additional, Ashby, L. S., additional, Cairncross, J. G., additional, Roldan, G. B., additional, Wen, P. Y., additional, Ligon, K. L., additional, Shiff, D., additional, Robins, H. I., additional, Rocque, B. G., additional, Mason, W. P., additional, Weaver, S. A., additional, Green, R. M., additional, Kamar, F. G., additional, Abrey, L. E., additional, DeAngelis, L. M., additional, Jhanwar, S. C., additional, Rosenblum, M. K., additional, Lassman, A. B., additional, Cachia, D., additional, Alderson, L., additional, Moser, R., additional, Smith, T., additional, Yunus, S., additional, Saito, K., additional, Mukasa, A., additional, Narita, Y., additional, Tabei, Y., additional, Shinoura, N., additional, Shibui, S., additional, Saito, N., additional, Flechl, B., additional, Ackerl, M., additional, Sax, C., additional, Dieckmann, K., additional, Crevenna, R., additional, Widhalm, G., additional, Preusser, M., additional, Marosi, C., additional, Ay, C., additional, Dunkler, D., additional, Pabinger, I., additional, Zielinski, C., additional, Belongia, M., additional, Jogal, S., additional, Schlingensiepen, K.-H., additional, Bogdahn, U., additional, Stockhammer, G., additional, Mahapatra, A. K., additional, Venkataramana, N. K., additional, Oliushine, V., additional, Parfenov, V., additional, Poverennova, I., additional, Hau, P., additional, Jachimczak, P., additional, Heinrichs, H., additional, Mammoser, A. G., additional, Shonka, N. A., additional, de Groot, J. F., additional, Shibahara, I., additional, Sonoda, Y., additional, Kumabe, T., additional, Saito, R., additional, Kanamori, M., additional, Yamashita, Y., additional, Watanabe, M., additional, Ishioka, C., additional, Tominaga, T., additional, Silvani, A., additional, Gaviani, P., additional, Lamperti, E., additional, Botturi, A., additional, DiMeco, F., additional, Broggi, G., additional, Fariselli, L., additional, Solero, C. L., additional, Salmaggi, A., additional, Woyshner, E. A., additional, Shu, F., additional, Oh, Y. S., additional, Iganej, S., additional, Singh, G., additional, Vemuri, S. L., additional, Theeler, B. J., additional, Ellezam, B., additional, Gilbert, M. R., additional, Aoki, T., additional, Kobayashi, H., additional, Takano, S., additional, Nishikawa, R., additional, Nagane, M., additional, Muragaki, Y., additional, Sugiyama, K., additional, Kuratsu, J., additional, Matsutani, M., additional, Langford, L. A., additional, Puduvalli, V. K., additional, Shen, D., additional, Chen, Z.-p., additional, Zhang, J.-p., additional, Bedekar, D., additional, Rand, S., additional, Connelly, J., additional, Malkin, M., additional, Paulson, E., additional, Mueller, W., additional, Schmainda, K., additional, Gallego, O., additional, Benavides, M., additional, Segura, P. P., additional, Balana, C., additional, Gil, M., additional, Berrocal, A., additional, Reynes, G., additional, Garcia, J. L., additional, Murata, P., additional, Bague, S., additional, Quintana, M. J., additional, Vasishta, V. G., additional, Kobayashi, K., additional, Tanaka, M., additional, Tsuchiya, K., additional, Shiokawa, Y., additional, Bavle, A. A., additional, Ayyanar, K., additional, Prado, M. P., additional, Hess, K. R., additional, Liu, V., additional, de Groot, J., additional, Loghin, M. E., additional, Colman, H., additional, Levin, V. A., additional, Alfred Yung, W. K., additional, Hackney, J. R., additional, Palmer, C. A., additional, Markert, J. M., additional, Cure, J., additional, Riley, K. O., additional, Fathallah-Shaykh, H., additional, Nabors, L. B., additional, Saria, M. G., additional, Corle, C., additional, Hu, J., additional, Rudnick, J., additional, Phuphanich, S., additional, Mrugala, M. M., additional, Lee, L. K., additional, Fu, B. D., additional, Bota, D. A., additional, Kim, R. Y., additional, Brown, T., additional, Feely, H., additional, Hu, A., additional, Lee, J. W., additional, Carter, B., additional, Kesari, S., additional, Kong, X.-T., additional, Sparagana, S., additional, Belousova, E., additional, Jozwiak, S., additional, Korf, B., additional, Frost, M., additional, Kuperman, R., additional, Kohrman, M., additional, Witt, O., additional, Wu, J., additional, Flamini, R., additional, Jansen, A., additional, Curtalolo, P., additional, Thiele, E., additional, Whittemore, V., additional, De Vries, P., additional, Ford, J., additional, Shah, G., additional, Cauwel, H., additional, Edrich, P., additional, Sahmoud, T., additional, Franz, D., additional, Khasraw, M., additional, Brown, C., additional, Ashley, D. M., additional, Rosenthal, M. A., additional, Jiang, X., additional, Mou, Y. g., additional, Chen, Z. p., additional, Oh, M., additional, kim, E., additional, Chang, J., additional, Juratli, T. A., additional, Kirsch, M., additional, Schackert, G., additional, Krex, D., additional, Wang, M., additional, Stupp, R., additional, Hegi, M., additional, Jaeckle, K. A., additional, Armstrong, T. S., additional, Wefel, J. S., additional, Won, M., additional, Blumenthal, D. T., additional, Mahajan, A., additional, Schultz, C. J., additional, Erridge, S. C., additional, Brown, P. D., additional, Chakravarti, A., additional, Curran, W. J., additional, Mehta, M. P., additional, Hofland, K. F., additional, Hansen, S., additional, Sorensen, M., additional, Schultz, H., additional, Muhic, A., additional, Engelholm, S., additional, Ask, A., additional, Kristiansen, C., additional, Thomsen, C., additional, Poulsen, H. S., additional, Lassen, U. N., additional, Zalatimo, O., additional, Weston, C., additional, Zoccoli, C., additional, Glantz, M., additional, Rahmanuddin, S., additional, Shiroishi, M. S., additional, Cen, S. Y., additional, Jones, J., additional, Chen, T., additional, Pagnini, P., additional, Go, J., additional, Lerner, A., additional, Gomez, J., additional, Law, M., additional, Ram, Z., additional, Wong, E. T., additional, Gutin, P. H., additional, Bobola, M. S., additional, Alnoor, M., additional, Silbergeld, D. L., additional, Rostomily, R. C., additional, Silber, J. R., additional, Martha, N., additional, Jacqueline, S., additional, Thaddaus, G., additional, Daniel, P., additional, Hans, M., additional, Armin, M., additional, Eugen, T., additional, Gunther, S., additional, Hutterer, M., additional, Tseng, H.-M., additional, Zoccoli, C. M., additional, Patel, A., additional, Rizzo, K., additional, Sheehan, J. M., additional, Sumrall, A. L., additional, Vredenburgh, J. J., additional, Desjardins, A., additional, Reardon, D. A., additional, Friiedman, H. S., additional, Peters, K. B., additional, Taylor, L. P., additional, Stewart, M., additional, Blondin, N. A., additional, Baehring, J. M., additional, Foote, T., additional, Laack, N., additional, Call, J., additional, Hamilton, M. G., additional, Walling, S., additional, Eliasziw, M., additional, Easaw, J., additional, Shirsat, N. V., additional, Kundar, R., additional, Gokhale, A., additional, Goel, A., additional, Moiyadi, A. A., additional, Wang, J., additional, Mutlu, E., additional, Oyan, A., additional, Yan, T., additional, Tsinkalovsky, O., additional, Jacobsen, H. K., additional, Talasila, K. M., additional, Sleire, L., additional, Pettersen, K., additional, Miletic, H., additional, Andersen, S., additional, Mitra, S., additional, Weissman, I., additional, Li, X., additional, Kalland, K.-H., additional, Enger, P. O., additional, Sepulveda, J., additional, Belda, C., additional, Sitt, R., additional, Phishniak, L., additional, Bokstein, F., additional, Philippe, M., additional, Carole, C., additional, Andre, M. d. P., additional, Marylin, B., additional, Olivier, C., additional, L'Houcine, O., additional, Dominique, F.-B., additional, Isabelle, N.-M., additional, Frederic, F., additional, Stephane, F., additional, Henry, D., additional, Errico, M. A., additional, Kunschner, L. J., additional, Soffietti, R., additional, Trevisan, E., additional, Ruda, R., additional, Bertero, L., additional, Bosa, C., additional, Fabrini, M. G., additional, Lolli, I., additional, Jalali, R., additional, Julka, P. K., additional, Anand, A. K., additional, Bhavsar, D., additional, Singhal, N., additional, Naik, R., additional, John, S., additional, Mathew, B. S., additional, Thaipisuttikul, I., additional, Graber, J., additional, Shirinian, M., additional, Fontebasso, A. M., additional, Jacob, K., additional, Gerges, N., additional, Montpetit, A., additional, Nantel, A., additional, Albrecht, S., additional, Jabado, N., additional, Shah, K., additional, Di, K., additional, Linskey, M., additional, Thon, N., additional, Eigenbrod, S., additional, Kreth, S., additional, Lutz, J., additional, Tonn, J.-C., additional, Kretzschmar, H., additional, Peraud, A., additional, Kreth, F.-W., additional, Muggeri, A. D., additional, Alderuccio, J. P., additional, Diez, B. D., additional, Jiang, P., additional, Chao, Y., additional, Gallagher, M., additional, Kim, R., additional, Pastorino, S., additional, Fogal, V., additional, Rudnick, J. D., additional, Bresee, C., additional, Rogatko, A., additional, Sakowsky, S., additional, Franco, M., additional, Lim, S., additional, Lopez, A., additional, Yu, L., additional, Ryback, K., additional, Tsang, V., additional, Lill, M., additional, Steinberg, A., additional, Sheth, R., additional, Grimm, S., additional, Helenowski, I., additional, Rademaker, A., additional, Nunes, F. P., additional, Merker, V., additional, Jennings, D., additional, Caruso, P., additional, Muzikansky, A., additional, Stemmer-Rachamimov, A., additional, Plotkin, S., additional, Spalding, A. C., additional, Vitaz, T. W., additional, Sun, D. A., additional, Parsons, S., additional, Welch, M. R., additional, Omuro, A., additional, Beal, K., additional, Correa, D., additional, Chan, T., additional, DeAngelis, L., additional, Gavrilovic, I., additional, Nolan, C., additional, Hormigo, A., additional, Kaley, T., additional, Mellinghoff, I., additional, Grommes, C., additional, Panageas, K., additional, Reiner, A., additional, Barradas, R., additional, Abrey, L., additional, Gutin, P., additional, Lee, S. Y., additional, Slagle-Webb, B., additional, Glantz, M. J., additional, Connor, J. R., additional, Schlimper, C. A., additional, Schlag, H., additional, Stoffels, G., additional, Weber, F., additional, Krueger, D. A., additional, Care, M. M., additional, Holland, K., additional, Agricola, K., additional, Tudor, C., additional, Byars, A., additional, Franz, D. N., additional, Rice, L., additional, Chandler, J., additional, Levy, R., additional, Muro, K., additional, Nayak, L., additional, Norden, A. D., additional, Kaley, T. J., additional, Thomas, A. A., additional, Fadul, C. E., additional, Meyer, L. P., additional, Lallana, E. C., additional, Gilbert, M., additional, Aldape, K., additional, De Groot, J., additional, Conrad, C., additional, Levin, V., additional, Groves, M., additional, Chris, P., additional, Puduvalli, V., additional, Nagpal, S., additional, Feroze, A., additional, Recht, L., additional, Rangarajan, H. G., additional, Kieran, M. W., additional, Scott, R. M., additional, Lew, S. M., additional, Firat, S. Y., additional, Segura, A. D., additional, Jogal, S. A., additional, Kumthekar, P. U., additional, Grimm, S. A., additional, Avram, M., additional, Patel, J., additional, Kaklamani, V., additional, McCarthy, K., additional, Cianfrocca, M., additional, Gradishar, W., additional, Mulcahy, M., additional, Von Roenn, J., additional, Galanis, E., additional, Anderson, S. K., additional, Lafky, J. M., additional, Kaufmann, T. J., additional, Uhm, J. H., additional, Giannini, C., additional, Kumar, S. K., additional, Northfelt, D. W., additional, Flynn, P. J., additional, Buckner, J. C., additional, Omar, A. I., additional, Schiff, D., additional, Delios, A., additional, Jakubowski, A., additional, Melguizo-Gavilanes, I., additional, Qiao, W., additional, Wang, X., additional, Hashemi-Sadraei, N., additional, Bawa, H., additional, Rahmathulla, G., additional, Patel, M., additional, Elson, P., additional, Stevens, G., additional, Peereboom, D., additional, Vogelbaum, M., additional, Weil, R., additional, Barnett, G., additional, Ahluwalia, M. S., additional, Alvord, E. C., additional, Rockne, R. C., additional, Rockhill, J. K., additional, Rostomily, R., additional, Lai, A., additional, Wardlaw, J., additional, Spence, A. M., additional, Swanson, K. R., additional, Zadeh, G., additional, Alahmadi, H., additional, Wilson, J., additional, Gentili, F., additional, Beumer, J. J., additional, Wright, J., additional, Takebe, N., additional, Gaur, R., additional, Werner-Wasik, M., additional, Gupta, A. J., additional, Campos-Gines, A., additional, Le, K., additional, Arango, C., additional, Richards, M., additional, Landeros, M., additional, Juan, H., additional, Chang, J. H., additional, Kim, J. S., additional, Cho, J. H., additional, Seo, C. O., additional, Baldock, A. L., additional, Rockne, R., additional, Canoll, P., additional, Born, D., additional, Yagle, K., additional, Alexandru, D., additional, Bota, D., additional, Linskey, M. E., additional, Nabeel, S., additional, Raval, S. N., additional, Rosenow, J., additional, Bredel, M., additional, New, P. Z., additional, Plotkin, S. R., additional, Supko, J. G., additional, Curry, W. T., additional, Chi, A. S., additional, Gerstner, E. R., additional, Batchelor, T. T., additional, Hashemi, N., additional, Chao, S. T., additional, Weil, R. J., additional, Suh, J. H., additional, Vogelbaum, M. A., additional, Stevens, G. H., additional, Barnett, G. H., additional, Corwin, D., additional, Holdsworth, C., additional, Stewart, R., additional, Swanson, K., additional, Graber, J. J., additional, Anderson, A. R., additional, Jeyapalan, S., additional, Goldman, M., additional, Boxerman, J., additional, Donahue, J., additional, Elinzano, H., additional, Evans, D., additional, O'Connor, B., additional, Puthawala, M. Y., additional, Oyelese, A., additional, Cielo, D., additional, Blitstein, M., additional, Dargush, M., additional, Santaniello, A., additional, Constantinou, M., additional, DiPetrillo, T., additional, Safran, H., additional, Halpin, C., additional, Barker, F. G., additional, Maher, E. A., additional, Ganji, S., additional, DeBerardinis, R., additional, Hatanpaa, K., additional, Rakheja, D., additional, Yang, X.-L., additional, Mashimo, T., additional, Raisanen, J., additional, Madden, C., additional, Mickey, B., additional, Malloy, C., additional, Bachoo, R., additional, Choi, C., additional, Ranjan, T., additional, Yono, N., additional, Han, S. J., additional, Sun, M., additional, Berger, M. S., additional, Aghi, M., additional, Gupta, N., additional, and Parsa, A. T., additional

Published
2011
Full Text
View/download PDF

44. Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: Preliminary results of the BOLERO-2 trial.

Author

Baselga, J., primary, Campone, M., additional, Piccart-Gebhart, M. J., additional, Burris, H. A., additional, Rugo, H. S., additional, Noguchi, S., additional, Gnant, M., additional, Pritchard, K. I., additional, Lebrun, F., additional, Beck, J. T., additional, Ito, Y., additional, Yardley, D. A., additional, Deleu, I., additional, Perez, A., additional, Bachelot, T. D., additional, Vittori, L., additional, Mukhopadhyay, P., additional, Weber, D., additional, Sahmoud, T., additional, and Hortobagyi, G. N., additional

Published
2011
Full Text
View/download PDF

47. Ongoing Clinical Trials

Author

Clarke, J. L., primary, Ennis, M. M., additional, Lamborn, K. R., additional, Prados, M. D., additional, Puduvalli, V. K., additional, Penas-Prado, M., additional, Gilbert, M. R., additional, Groves, M. D., additional, Hess, K. R., additional, Levin, V. A., additional, de Groot, J., additional, Colman, H., additional, Conrad, C. A., additional, Loghin, M. E., additional, Hunter, K., additional, Yung, W. K., additional, Chen, C., additional, Damek, D., additional, Liu, A., additional, Gaspar, L. E., additional, Waziri, A., additional, Lillehei, K., additional, Kavanagh, B., additional, Finlay, J. L., additional, Haley, K., additional, Dhall, G., additional, Gardner, S., additional, Allen, J., additional, Cornelius, A., additional, Olshefski, R., additional, Garvin, J., additional, Pradhan, K., additional, Etzl, M., additional, Goldman, S., additional, Atlas, M., additional, Thompson, S., additional, Hirt, A., additional, Hukin, J., additional, Comito, M., additional, Bertolone, S., additional, Torkildson, J., additional, Joyce, M., additional, Moertel, C., additional, Letterio, J., additional, Kennedy, G., additional, Walter, A., additional, Ji, L., additional, Sposto, R., additional, Dorris, K., additional, Wagner, L., additional, Hummel, T., additional, Drissi, R., additional, Miles, L., additional, Leach, J., additional, Chow, L., additional, Turner, R., additional, Gragert, M. N., additional, Pruitt, D., additional, Sutton, M., additional, Breneman, J., additional, Crone, K., additional, Fouladi, M., additional, Friday, B. B., additional, Buckner, J., additional, Anderson, S. K., additional, Giannini, C., additional, Kugler, J., additional, Mazurczac, M., additional, Flynn, P., additional, Gross, H., additional, Pajon, E., additional, Jaeckle, K., additional, Galanis, E., additional, Badruddoja, M. A., additional, Pazzi, M. A., additional, Stea, B., additional, Lefferts, P., additional, Contreras, N., additional, Bishop, M., additional, Seeger, J., additional, Carmody, R., additional, Rance, N., additional, Marsella, M., additional, Schroeder, K., additional, Sanan, A., additional, Swinnen, L. J., additional, Rankin, C., additional, Rushing, E. J., additional, Hutchins, L. F., additional, Damek, D. M., additional, Barger, G. R., additional, Norden, A. D., additional, Lesser, G., additional, Hammond, S. N., additional, Drappatz, J., additional, Fadul, C. E., additional, Batchelor, T. T., additional, Quant, E. C., additional, Beroukhim, R., additional, Ciampa, A., additional, Doherty, L., additional, LaFrankie, D., additional, Ruland, S., additional, Bochacki, C., additional, Phan, P., additional, Faroh, E., additional, McNamara, B., additional, David, K., additional, Rosenfeld, M. R., additional, Wen, P. Y., additional, Phuphanich, S., additional, Reardon, D., additional, Wong, E. T., additional, Plotkin, S. R., additional, Mintz, A., additional, Raizer, J. J., additional, Kaley, T. J., additional, Smith, K. H., additional, Chamberlain, M. C., additional, Graham, C., additional, Mrugala, M., additional, Johnston, S., additional, Kreisl, T. N., additional, Smith, P., additional, Iwamoto, F., additional, Sul, J., additional, Butman, J. A., additional, Fine, H. A., additional, Westphal, M., additional, Heese, O., additional, Warmuth-Metz, M., additional, Pietsch, T., additional, Schlegel, U., additional, Tonn, J.-C., additional, Schramm, J., additional, Schackert, G., additional, Melms, A., additional, Mehdorn, H. M., additional, Seifert, V., additional, Geletneky, K., additional, Reuter, D., additional, Bach, F., additional, Khasraw, M., additional, Abrey, L. E., additional, Lassman, A. B., additional, Hormigo, A., additional, Nolan, C., additional, Gavrilovic, I. T., additional, Mellinghoff, I. K., additional, Reiner, A. S., additional, DeAngelis, L., additional, Omuro, A. M., additional, Burzynski, S. R., additional, Weaver, R. A., additional, Janicki, T. J., additional, Burzynski, G. S., additional, Szymkowski, B., additional, Acelar, S. S., additional, Mechtler, L. L., additional, O'Connor, P. C., additional, Kroon, H.-A., additional, Vora, T., additional, Kurkure, P., additional, Arora, B., additional, Gupta, T., additional, Dhamankar, V., additional, Banavali, S., additional, Moiyadi, A., additional, Epari, S., additional, Merchant, N., additional, Jalali, R., additional, Moller, S., additional, Grunnet, K., additional, Hansen, S., additional, Schultz, H., additional, Holmberg, M., additional, Sorensen, M. M., additional, Poulsen, H. S., additional, Lassen, U., additional, Reardon, D. A., additional, Vredenburgh, J. J., additional, Desjardins, A., additional, Janney, D. E., additional, Peters, K., additional, Sampson, J., additional, Gururangan, S., additional, Friedman, H. S., additional, Jeyapalan, S., additional, Constantinou, M., additional, Evans, D., additional, Elinzano, H., additional, O'Connor, B., additional, Puthawala, M. Y., additional, Goldman, M., additional, Oyelese, A., additional, Cielo, D., additional, Dipetrillo, T., additional, Safran, H., additional, Anan, M., additional, Seyed Sadr, M., additional, Alshami, J., additional, Sabau, C., additional, Seyed Sadr, E., additional, Siu, V., additional, Guiot, M.-C., additional, Samani, A., additional, Del Maestro, R., additional, Bogdahn, U., additional, Stockhammer, G., additional, Mahapatra, A. K., additional, Venkataramana, N. K., additional, Oliushine, V. E., additional, Parfenov, V. E., additional, Poverennova, I. E., additional, Hau, P., additional, Jachimczak, P., additional, Heinrichs, H., additional, Schlingensiepen, K.-H., additional, Shibui, S., additional, Kayama, T., additional, Wakabayashi, T., additional, Nishikawa, R., additional, de Groot, M., additional, Aronica, E., additional, Vecht, C. J., additional, Toering, S. T., additional, Heimans, J. J., additional, Reijneveld, J. C., additional, Batchelor, T., additional, Mulholland, P., additional, Neyns, B., additional, Nabors, L. B., additional, Campone, M., additional, Wick, A., additional, Mason, W., additional, Mikkelsen, T., additional, Ashby, L. S., additional, DeGroot, J. F., additional, Gattamaneni, H. R., additional, Cher, L. M., additional, Rosenthal, M. A., additional, Payer, F., additional, Xu, J., additional, Liu, Q., additional, van den Bent, M., additional, Nabors, B., additional, Fink, K., additional, Chan, M., additional, Trusheim, J., additional, Raval, S., additional, Hicking, C., additional, Henslee-Downey, J., additional, Picard, M., additional, Schiff, D., additional, Karimi, S., additional, DeAngelis, L. M., additional, Nolan, C. P., additional, Omuro, A., additional, Gavrilovic, I., additional, Norden, A., additional, Purow, B. W., additional, Lieberman, F. S., additional, Hariharan, S., additional, Perez-Larraya, J. G., additional, Honnorat, J., additional, Chinot, O., additional, Catry-Thomas, I., additional, Taillandier, L., additional, Guillamo, J. S., additional, Campello, C., additional, Monjour, A., additional, Tanguy, M. L., additional, Delattre, J. Y., additional, Franz, D. N., additional, Krueger, D. A., additional, Care, M. M., additional, Holland-Bouley, K., additional, Agricola, K., additional, Tudor, C., additional, Mangeshkar, P., additional, Byars, A. W., additional, Sahmoud, T., additional, Alonso-Basanta, M., additional, Lustig, R. A., additional, Dorsey, J. F., additional, Lai, R. K., additional, Recht, L. D., additional, Paleologos, N., additional, Groves, M., additional, Meech, S., additional, Davis, T., additional, Pavlov, D., additional, Marshall, M. A., additional, Slot, M., additional, Peerdeman, S. M., additional, Beauchesne, P. D., additional, Faure, G., additional, Noel, G., additional, Schmitt, T., additional, Kerr, C., additional, Jadaud, E., additional, Martin, L., additional, Carnin, C., additional, Peters, K. B., additional, Herndon, J. E., additional, Kirkpatrick, J. P., additional, Nayak, L., additional, Panageas, K. S., additional, and Deangelis, L. M., additional

Published
2010
Full Text
View/download PDF

48. Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial.

Author

Dalenc, F., primary, Campone, M., additional, Hupperets, P., additional, O'Regan, R., additional, Manlius, C., additional, Vittori, L., additional, Mukhopadhyay, P., additional, Massacesi, C., additional, Sahmoud, T., additional, and Andre, F., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results